12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Seattle Genetics preclinical data

In a mouse model of AML, a single dose of 300 µg/kg SGN-CD33A produced durable complete regressions in multidrug-resistant-positive and multidrug-resistant-negative cell lines. Additionally, a single dose of 1,000 µg/kg SGN-CD33A significantly delayed tumor growth compared to non-binding and untreated controls (p<0.001). A single dose of...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >